


Product Name : (±)-Zanubrutinib
Cat. No. : PC-42396
CAS No. : 1633350-06-7
Molecular Formula : C₂₇H₂₉N₅O₃
Molecular Weight : 471.55086
Target : BTK
Solubility : 10 mM in DMSO



Biological Activity

The active enantiomer of Zanubrutinib (BGB3111), a potent, selective and orally available **Btk** inhibitor; shows much more restricted off-target activities against a panel of kinases, including ITK, compared with Ibrutinib; demonstrates nanomolar BTK inhibition activity, inhibits BCR aggregation-triggered BTK autophosphorylation, blocks downstream PLC- γ 2 signaling, and potently inhibits cell proliferation in several MCL and DLBCL cell lines; demonstrates better anti-tumor activity than ibrutinib in TMD-8 subcutaneous xenograft model.

Blood Cancer
Phase 3 Clinical

References

Na Li, et al. Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor. AACR.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com